Benlysta class action fails on lack of evidence; Merck KGaA, Bayer arrange new debt financing;

@FiercePharma: Pfizer's targeted lung cancer drug Xalkori too expensive, U.K. cost-effectiveness body says. More | Follow @FiercePharma

@EricPFierce: Teva, Samsung face biosimilar realities. The business is not for the "faint of heart," but has great potential. More | Follow @EricPFierce

> GlaxoSmithKline ($GSK) and Human Genome Sciences won't have to face a class action accusing them of concealing alleged risks of their lupus drug Benlysta, after a judge ruled there wasn't enough evidence that the companies hid suicide reports. Report

> Merck KGaA replaced a €2 billion loan facility with long-term financing. Report

> Bayer priced a $200 million debt issue maturing in 2016. Report

> Children on Medicaid were prescribed antipsychotic drugs 5 times more often than privately-ensured children, a new study found, and many of those prescriptions were for off-label, behavioral uses. Report

> The FDA plans to monitor the Internet to keep a lid on illicit sales of prescription drugs, tobacco and other regulated products. Report

> A Chinese court urged government regulators to better monitor pharmaceutical companies' insurance coverage for compensating patients harmed during clinical trials. Report

> GlaxoSmithKline CEO Andrew Witty touted his company's new Philadelphia-area headquarters in an interview with the Philadelphia Inquirer. Report

Biotech News

 @FierceBiotech: Guest post by Lee Feigenbaum on Big Data sheds light on pharma's 'Small Data' problems. Industry Voices | Follow @FierceBiotech

@JohnCFierce: Blessed by Gates, crowdfunding site funnels cash for high-risk R&D. Report | Follow @JohnCFierce

@RyanMFierce: Aastrom sinks after biotech flushes PhIII study for cardio therapy, halves staff. News | Follow @RyanMFierce

> Sarepta's high-noon decision on eteplirsen draws a big biotech crowd. Story

> Little-known Reviva attracts a big angel crowd for $12M CNS round. More

> What's in a cancer drug name? Maybe a $1.5M cash windfall for researchers. Article

Medical Device News

 @FierceMedDev: Next-gen prostate cancer Dx faces skepticism, competition. Story | Follow @FierceMedDev

 @MarkHFierce: Some companies are shedding drug operations to focus more on devices, while BD is adding a (generic) drug arm. Press release | Follow @MarkHFierce

 @DamianFierce: Intuitive Surgical will have its day in court after a judge ruled to allow a patient's suit. News | Follow @DamianFierce

> As sale rumors abound, Life Tech expands in China. More

> Quidel gains CE mark for herpes/chicken pox molecular Dx. Story

> Becton Dickinson jumps into generic drug business. Article

Drug Delivery News

@MichaelGFierce: FierceDrugDelivery Special Report: Drug-Delivery Device Combos to Watch. Report | Follow @MichaelGFierce

> FDA approves Novartis' inhaled powder drug for cystic fibrosis infection. Story

> Intarcia enrolls PhIII glucose control study for Type 2 diabetes. Item

> Nanoparticles deliver cancer drug, spare fertility. News

> FDA panel OKs Titan's addiction drug delivery platform. More

And Finally... Long-lived Greek islanders may have their boiled coffee to thank, researchers say, though they also eat healthy foods and exercise regularly. Report

Suggested Articles

After global recalls of heartburn medicine Zantac and an FDA ban, the Department of Justice is investigating Sanofi and GlaxoSmithKline.

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.